|
|
|
Home >
Health Conditions > Diabetes > Onglyza
(saxagliptin)
Onglyza (saxagliptin)
Related Topics:
News & Research:
-
FDA Warns of Heart
Failure Risk With Two Diabetes Drugs - Medscape, 4/5/16 -
"Health care professionals should consider
discontinuing medications containing saxagliptin and alogliptin in patients
who develop heart failure and monitor their diabetes control ... In the
saxagliptin trial, which included 16,492 patients with type 2 diabetes and
established cardiovascular disease or who were at high risk for
cardiovascular disease, there was no overall risk for cardiovascular events,
but there was a 27% increase (3.5% vs. 2.8%) in the rate of the first event
of hospitalization for heart failure and a potential increased risk for
all-cause mortality"
-
Metformin vs. Sulfonylureas for Diabetes - WebMD, 12/4/09 -
"Researchers reported that diabetes patients who
used sulfonylureas had a higher risk of death from all causes and a higher
risk of heart failure than diabetes patients who used the most widely
prescribed diabetes drug, metformin ... Compared with metformin, also known
as Glucophage, single-drug treatment with first- and second-generation
sulfonylureas was associated with up to a 61% increased risk for death.
Users of second-generation sulfonylureas had up to a 30% higher risk for
congestive heart failure ... Patients treated with Actos or Avandia did not
appear to have a greater risk for heart attacks than those treated with
metformin"
-
FDA Approves Saxagliptin for Type 2 Diabetes - Doctor's Guide, 7/31/09 -
"Although saxagliptin was not associated with an
increased risk for cardiovascular events in patients who were mainly at low
risk for these events, the FDA is requiring a post-market study that will
specifically evaluate cardiovascular safety in a higher risk population"
Related Searches:
70526
|
|
